Literature DB >> 23079804

Changes in sexual and drug-related risk behavior following antiretroviral therapy initiation among HIV-infected injection drug users.

Tsung-chieh Fu1, Ryan P Westergaard, Bryan Lau, David D Celentano, David Vlahov, Shruti H Mehta, Gregory D Kirk.   

Abstract

OBJECTIVE: To evaluate whether HAART is associated with subsequent sexual and drug-related risk behavior compensation among injection drug users (IDUs).
DESIGN: A community-based cohort study of 362 HIV-infected IDUs initiating HAART in Baltimore, Maryland.
METHODS: HAART use and risk behavior was assessed at 8316 biannual study visits (median 23). Using logistic regression with generalized estimating equations (GEE), we examined the effect of HAART initiation on changes in risk behavior while adjusting for sociodemographics, alcohol use, CD4 cell count, year of initiation and consistency of HAART use.
RESULTS: At HAART initiation, participants were a median of 44.4 years old, 71.3% men and 95.3% African-American. In multivariable analysis, HAART initiation was associated with a 75% reduction in the likelihood of unprotected sex [adjusted odds ratio (aOR) 0.25; 95% confidence interval (CI), 0.19-0.32] despite no change in overall sexual activity (aOR 0.95; 0.80-1.12). Odds of any injecting decreased by 38% (aOR 0.62; 0.51-0.75) after HAART initiation. Among the subset of persistent injectors, needle-sharing increased nearly two-fold (aOR 1.99; 1.57-2.52). Behavioral changes were sustained for more than 5 years after HAART initiation and did not differ by consistency of HAART use. Reporting specific high-risk behaviors in the year prior to initiation was a robust predictor of engaging in those behaviors subsequent to HAART.
CONCLUSION: Overall, substantial declines in sexual risk-taking and active injecting argue against significant behavioral compensation among IDUs following HAART initiation. These data also provide evidence to support identifying persons with risky pre-HAART behavior for targeted behavioral intervention.

Entities:  

Mesh:

Year:  2012        PMID: 23079804      PMCID: PMC3678983          DOI: 10.1097/QAD.0b013e32835ad438

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  46 in total

1.  Modelling the effect of combination antiretroviral treatments on HIV incidence.

Authors:  M G Law; G Prestage; A Grulich; P Van de Ven; S Kippax
Journal:  AIDS       Date:  2001-07-06       Impact factor: 4.177

2.  Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users.

Authors:  Grace E Macalino; David D Celentano; Carl Latkin; Steffanie A Strathdee; David Vlahov
Journal:  AIDS Educ Prev       Date:  2002-10

Review 3.  Could widespread use of combination antiretroviral therapy eradicate HIV epidemics?

Authors:  J X Velasco-Hernandez; H B Gershengorn; S M Blower
Journal:  Lancet Infect Dis       Date:  2002-08       Impact factor: 25.071

4.  Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study.

Authors:  Catharina E A Lindenburg; Anneke Krol; Colette Smit; Marcel C A Buster; Roel A Coutinho; Maria Prins
Journal:  AIDS       Date:  2006-08-22       Impact factor: 4.177

5.  Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users.

Authors:  D Vlahov; M Safaien; S Lai; S A Strathdee; L Johnson; T Sterling; D D Celentano
Journal:  AIDS       Date:  2001-11-23       Impact factor: 4.177

6.  Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users.

Authors:  D D Celentano; N Galai; A K Sethi; N G Shah; S A Strathdee; D Vlahov; J E Gallant
Journal:  AIDS       Date:  2001-09-07       Impact factor: 4.177

7.  Does initiation of HIV antiretroviral therapy influence patterns of syringe lending among injection drug users?

Authors:  Laura Kuyper; M-J Milloy; Brandon D L Marshall; Ruth Zhang; Thomas Kerr; Julio S G Montaner; Evan Wood
Journal:  Addict Behav       Date:  2011-01-21       Impact factor: 3.913

8.  Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men.

Authors:  David E Ostrow; Kelly J Fox; Joan S Chmiel; Anthony Silvestre; Barbara R Visscher; Peter A Vanable; Lisa P Jacobson; Steffanie A Strathdee
Journal:  AIDS       Date:  2002-03-29       Impact factor: 4.177

9.  Modelling the impact of antiretroviral use in resource-poor settings.

Authors:  Rebecca F Baggaley; Geoff P Garnett; Neil M Ferguson
Journal:  PLoS Med       Date:  2006-03-14       Impact factor: 11.069

10.  Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts.

Authors:  John D Morris; Elizabeth T Golub; Shruti H Mehta; Lisa P Jacobson; Stephen J Gange
Journal:  AIDS Res Ther       Date:  2007-06-06       Impact factor: 2.250

View more
  11 in total

Review 1.  Adherence to antiretroviral medications among persons who inject drugs in transitional, low and middle income countries: an international systematic review.

Authors:  Jonathan Feelemyer; Don Des Jarlais; Kamyar Arasteh; Anneli Uusküla
Journal:  AIDS Behav       Date:  2015-04

2.  Putting risk compensation to rest: reframing the relationship between risk behavior and antiretroviral therapy among injection drug users.

Authors:  Brandon D L Marshall; Evan Wood
Journal:  AIDS       Date:  2012-11-28       Impact factor: 4.177

3.  The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients.

Authors:  E Jennifer Edelman; Tongtan Chantarat; Sarah Caffrey; Amina Chaudhry; Patrick G O'Connor; Linda Weiss; David A Fiellin; Lynn E Fiellin
Journal:  Drug Alcohol Depend       Date:  2014-03-15       Impact factor: 4.492

4.  Association of Injection Practices and Overdose With Drug Use Typologies: A Latent Class Analysis Among People Who Inject Drugs in Baltimore, 2017.

Authors:  Rachel E Gicquelais; Becky L Genberg; Jacquie Astemborski; David D Celentano; Gregory D Kirk; Shruti H Mehta
Journal:  AIDS Educ Prev       Date:  2019-08

5.  Smartphone Delivery of Mobile HIV Risk Reduction Education.

Authors:  Karran A Phillips; David H Epstein; Mustapha Mezghanni; Massoud Vahabzadeh; David Reamer; Daniel Agage; Kenzie L Preston
Journal:  AIDS Res Treat       Date:  2013-09-17

6.  Factors Associated with HIV Testing History among Pregnant Women and Their Partners in Georgia: The ANRS 12127 Prenahtest Trial.

Authors:  Maia Butsashvili; Maia Kajaia; George Kamkamidze; Patrice Tchendjou; Annabel Desgrees du Loû; François Dabis; Joanna Orne-Gliemann
Journal:  AIDS Res Treat       Date:  2014-09-29

7.  Integrating Cervical Cancer Screening with HIV Care in Cameroon: Comparative Risk Analysis of Cervical Disease in HIV-Infected Women Receiving Antiretroviral Therapy to Women in the General Population.

Authors:  Cavin Epie Bekolo; Gillian O'Bryan; François Edmond Tchago; Charlette Nangue; Patrick Sylvestre Bekoule; Basile Kollo
Journal:  PLoS One       Date:  2016-02-11       Impact factor: 3.240

8.  Risky sexual practice and associated factors among HIV positive adults attending anti-retroviral treatment clinic at Gondar University Referral Hospital, Northwest Ethiopia.

Authors:  Abiyot Abeje Molla; Abebaw Addis Gelagay
Journal:  PLoS One       Date:  2017-03-28       Impact factor: 3.240

9.  HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel.

Authors:  Jeanne M Marrazzo; Carlos del Rio; David R Holtgrave; Myron S Cohen; Seth C Kalichman; Kenneth H Mayer; Julio S G Montaner; Darrell P Wheeler; Robert M Grant; Beatriz Grinsztejn; N Kumarasamy; Steven Shoptaw; Rochelle P Walensky; Francois Dabis; Jeremy Sugarman; Constance A Benson
Journal:  JAMA       Date:  2014 Jul 23-30       Impact factor: 56.272

10.  Inconsistent condom use among HIV-positive women in the "Treatment as Prevention Era": data from the Italian DIDI study.

Authors:  Paola Cicconi; Antonella d'Arminio Monforte; Antonella Castagna; Tiziana Quirino; Anna Alessandrini; Miriam Gargiulo; Daniela Francisci; Enza Anzalone; Giuseppina Liuzzi; Paola Pierro; Adriana Ammassari
Journal:  J Int AIDS Soc       Date:  2013-10-16       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.